Details for Patent: 7,196,205
✉ Email this page to a colleague
Title: | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
Abstract: | Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis. |
Inventor(s): | Siegel; Craig (Woburn, MA), Shayman; James A. (Ann Arbor, MI), Nelson; Carol A. (Westford, MA), Harris; David J. (Lexington, MA), Copeland; Diane P. (North Billerica, MA) |
Assignee: | The Regents of the University of Michigan (Ann Arbor, MI) Genzyme Corporation (Cambridge, MA) |
Filing Date: | Mar 28, 2005 |
Application Number: | 11/091,836 |
Claims: | 1. A compound represented by the following structural formula: ##STR00033## or a physiologically acceptable salt thereof. 2. A compound represented by the following structural formula: ##STR00034## or a physiologically acceptable salt thereof. 3. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 10%. 4. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 25%. 5. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 50%. 6. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 75%. 7. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 90%. 8. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 95%. 9. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 99%. 10. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 10%. 11. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 25%. 12. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 50%. 13. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 75%. 14. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 90%. 15. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 95%. 16. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 99%. |